Therapeutic potential of⁹⁰Y- and¹³¹I-labeled anti-CD20 monoclonal antibody in treating non-Hodgkin's lymphoma with pulmonary involvement: A Monte Carlo-based dosimetric analysis

Medicine and Dentistry

• Neoplasm 100%
• Non-Hodgkin Lymphoma 100%
• Rituximab 100%
• Iodine 131 68%
• Yttrium 90 62%
• Absorbed Dose 37%
• Lung Metastasis 25%
• Dosimetry 12%
• Combination Therapy 12%
• Metastatic Carcinoma 6%
• Targeted Therapy 6%
• Lung Tumor 6%
• Therapeutic Window 6%
• Radioisotope 6%
• Lung Parenchyma 6%
• Tositumomab 6%
• Patient with Non-Hodgkins Lymphoma 6%
• Ibritumomab Tiuxetan 6%
• CD20 Antibody 6%

Pharmacology, Toxicology and Pharmaceutical Science

• Neoplasm 100%
• Nonhodgkin Lymphoma 100%
• Rituximab 100%
• Iodine-131 68%
• Yttrium 90 62%
• Lung Metastasis 25%
• Combination Therapy 12%
• Dosimetry 12%
• Metastasis 6%
• Lung Tumor 6%
• Therapeutic Window 6%
• Radioisotope 6%
• Tositumomab 6%
• Ibritumomab Tiuxetan 6%
• CD20 Antibody 6%

Keyphrases

• MCNP4B 9%